Amicus Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 517
- Market Cap
- $3.3B
- Website
- http://www.amicusrx.com
- Introduction
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 84
- Registration Number
- NCT02194985
- Locations
- 🇬🇧
Clinical Study Site, London, United Kingdom
A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-03-10
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 31
- Registration Number
- NCT02082327
- Locations
- 🇳🇱
PRA International, Groningen, Netherlands
A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT01853852
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia
A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 6
- Registration Number
- NCT01730482
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 32
- Registration Number
- NCT01730469
- Locations
- 🇺🇸
GSK Investigational Site, Orlando, Florida, United States
Migalastat Food Effect Study
- Conditions
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT01489995
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease
- Conditions
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Amicus Therapeutics
- Registration Number
- NCT01476163
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸CHOC Children's Hospital Division of Metabolic Disease, Orange, California, United States
🇦🇺Royal Melbourne Hospital, Parkville, Victoria, Australia
Open-Label Phase 3 Long-Term Safety Study of Migalastat
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 85
- Registration Number
- NCT01458119
Drug-drug Interaction Study
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT01380743
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
- Conditions
- Interventions
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 68
- Registration Number
- NCT01218659